Skip to main content

Fiscal Wizard · Single-issue tearsheet

ADTX / Jun 21, 2026 Run #7359

ADTX

Aditxt, Inc.

Aditxt, Inc. focuses on discovery and development of biopharmaceutical products. The company develops AditxtScore and FlowSpot that enable individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It develops ADI-100 for skin grafting, psoriasis, and type-1 diabetes. In addition, the company provides Pearsanta that develops molecular tests based on the mitochondrial DNA (mtDNA) to develop tests for early detection of cancer; Mitomic targets mutations in mitochondrial DNA (mtDNA) to detect disease; Mitomic prostate test a blood-based assay that quantifies the level of the 3.4kb mtDNA deletion; and Mitomic endometriosis test, a blood-based assay that quantifies the level of one or more mtDNA deletions. Further, it offers Adivir for commercial development of products to address significant unmet needs in infectious disease and population health; and Adifem address critical unmet needs in women health. The company has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Mountain View, California.

Composite verdict

F 13.4 / 100
Bearish setup · Directional State 2 drivers · 6 gates blocking
  • Relative Strength vs SPY
  • Chaikin Money Flow
Consider long put target Δ ~0.60 · ~35 DTE Bearish setup, Grade B → ITM put target

Industry rank 388th of 598 in Biotechnology

rescore-sweep
Technical synthesisRegime: volatile downtrend
Bull 0%Evidence: High · 17 signals100% Bear
Momentum Bearish 16Mean-reversion Neutral 50
  • Late-stage trendTrend signals have been live for 474 bars — past the ~60-bar window; momentum edge decays and can reverse late in a move. (medium confidence)
Where value comes from

Earnings power doesn't cover the capital structure (high debt) — the EPV decomposition isn't meaningful for this name.

Fundamentals Weak

10.6 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
EPS Growth (YoY) 100
Return on Capital Employed 0
EV/Sales 75
Return on Assets 0
P/S Ratio 75
Free Cash Flow Yield 0

Technicals Bearish

16.1 / 100

Bearish setup leads (Relative Strength vs SPY, Chaikin Money Flow, Accumulation/Distribution Line); bulls gated by guards. · 43 signals shown.

Strongest
Weakest
Relative Strength vs SPY 33
Chaikin Money Flow 34

Risk Gates

6 blocking 3 caution

6 guards active, 22 signals gated.

Altman Z-Score Blocking

Bottom-band Altman Z blocks bullish signals — distress risk.

Interest Coverage Blocking

Weak interest coverage blocks bullish signals — debt-service risk.

Piotroski F-Score Blocking

Bottom-band Piotroski F blocks bullish signals — fundamental-quality risk.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for ADTX.